NEW YORK (GenomeWeb) – Bio-Techne today announced a strategic agreement with China's Lisen Imprinting Diagnostics Wuxi in the field of precision medicine.
Specifically, the partnership, Minneapolis-based Bio-Techne said, will accelerate the development of molecular diagnostics in the Chinese market. Financial and other terms of the agreement were not disclosed.